PL4324522T3 - Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek - Google Patents

Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek

Info

Publication number: PL4324522T3
Authority: PL; Poland
Prior art keywords: methods; renal impairment; fabry patients; treating fabry; treating
Prior art date: 2017-05-30

Application number

PL23219949.7T

Other languages

English (en)

Inventor

Jeff Castelli

Original Assignee

Amicus Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-30

Filing date

2018-05-30

Publication date

2026-04-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4324522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-30 Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.

2026-04-27 Publication of PL4324522T3 publication Critical patent/PL4324522T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL23219949.7T 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek PL4324522T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762512458P	2017-05-30	2017-05-30
US201862626953P	2018-02-06	2018-02-06

Publications (1)

Publication Number	Publication Date
PL4324522T3 true PL4324522T3 (pl)	2026-04-27

Family

ID=65803261

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL22165669.7T PL4062916T3 (pl)	2017-05-30	2018-05-30	Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
PL23219933.1T PL4327869T3 (pl)	2017-05-30	2018-05-30	Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL23219949.7T PL4324522T3 (pl)	2017-05-30	2018-05-30	Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL18733415.6T PL3630114T3 (pl)	2017-05-30	2018-05-30	Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL22165669.7T PL4062916T3 (pl)	2017-05-30	2018-05-30	Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
PL23219933.1T PL4327869T3 (pl)	2017-05-30	2018-05-30	Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18733415.6T PL3630114T3 (pl)	2017-05-30	2018-05-30	Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Country Status (14)

Country	Link
EP (9)	EP3630114B9 (pl)
CN (4)	CN111278438A (pl)
DK (4)	DK4324522T3 (pl)
ES (5)	ES3002433T3 (pl)
FI (4)	FI4062916T3 (pl)
HR (4)	HRP20260346T1 (pl)
HU (2)	HUE069837T2 (pl)
LT (4)	LT4324522T (pl)
PL (4)	PL4062916T3 (pl)
PT (4)	PT4062916T (pl)
RS (4)	RS67861B1 (pl)
SI (4)	SI4327869T1 (pl)
SM (4)	SMT202600114T1 (pl)
TW (4)	TWI894750B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220313670A1 (en) *	2019-06-11	2022-10-06	Amicus Therapeutics, Inc.	Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) *	2019-08-07	2022-04-08	아미쿠스 세라퓨틱스, 인코포레이티드	Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) *	2006-05-16	2017-09-26	Nat Institutes Of Health	Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en)	2007-03-30	2010-11-10	Amicus Therapeutics Inc	METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) *	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) *	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) *	2008-02-12	2009-08-20	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) *	2011-03-11	2012-09-20	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) *	2011-05-06	2012-11-08	Amicus Therapeutics Inc.	Quantitation of gl3 in urine
WO2018017721A1 (en)	2016-07-19	2018-01-25	Amicus Therapeutics, Inc.	Treatment of fabry disease in ert-naïve and ert-experienced patients
AU2018277756A1 (en)	2017-05-30	2020-01-23	Amicus Therapeutics, Inc.	Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) *	2017-07-19	2020-05-26	Амикус Терапьютикс, Инк.	Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

2018
- 2018-05-30 PL PL22165669.7T patent/PL4062916T3/pl unknown
- 2018-05-30 FI FIEP22165669.7T patent/FI4062916T3/fi active
- 2018-05-30 SM SM20260114T patent/SMT202600114T1/it unknown
- 2018-05-30 LT LTEP23219949.7T patent/LT4324522T/lt unknown
- 2018-05-30 CN CN201880043564.XA patent/CN111278438A/zh active Pending
- 2018-05-30 PL PL23219933.1T patent/PL4327869T3/pl unknown
- 2018-05-30 SI SI201831311T patent/SI4327869T1/sl unknown
- 2018-05-30 HR HRP20260346TT patent/HRP20260346T1/hr unknown
- 2018-05-30 EP EP18733415.6A patent/EP3630114B9/en active Active
- 2018-05-30 SI SI201831310T patent/SI4324522T1/sl unknown
- 2018-05-30 EP EP25176976.6A patent/EP4635496A1/en active Pending
- 2018-05-30 TW TW112150982A patent/TWI894750B/zh active
- 2018-05-30 CN CN202411682885.8A patent/CN119587544A/zh active Pending
- 2018-05-30 SM SM20240037T patent/SMT202400037T1/it unknown
- 2018-05-30 DK DK23219949.7T patent/DK4324522T3/da active
- 2018-05-30 TW TW112104527A patent/TW202322814A/zh unknown
- 2018-05-30 ES ES22165669T patent/ES3002433T3/es active Active
- 2018-05-30 DK DK18733415.6T patent/DK3630114T3/da active
- 2018-05-30 EP EP23219933.1A patent/EP4327869B1/en active Active
- 2018-05-30 RS RS20260301A patent/RS67861B1/sr unknown
- 2018-05-30 PT PT221656697T patent/PT4062916T/pt unknown
- 2018-05-30 PL PL23219949.7T patent/PL4324522T3/pl unknown
- 2018-05-30 ES ES24164126T patent/ES3052647T3/es active Active
- 2018-05-30 HU HUE22165669A patent/HUE069837T2/hu unknown
- 2018-05-30 RS RS20250010A patent/RS66376B1/sr unknown
- 2018-05-30 HR HRP20240061TT patent/HRP20240061T1/hr unknown
- 2018-05-30 SM SM20260113T patent/SMT202600113T1/it unknown
- 2018-05-30 FI FIEP18733415.6T patent/FI3630114T3/fi active
- 2018-05-30 EP EP22165669.7A patent/EP4062916B1/en active Active
- 2018-05-30 HU HUE18733415A patent/HUE065615T2/hu unknown
- 2018-05-30 SI SI201831193T patent/SI4062916T1/sl unknown
- 2018-05-30 EP EP24164126.5A patent/EP4374918B1/en active Active
- 2018-05-30 RS RS20260292A patent/RS67849B1/sr unknown
- 2018-05-30 TW TW110119149A patent/TWI775453B/zh active
- 2018-05-30 SM SM20250016T patent/SMT202500016T1/it unknown
- 2018-05-30 PT PT187334156T patent/PT3630114T/pt unknown
- 2018-05-30 FI FIEP23219949.7T patent/FI4324522T3/fi active
- 2018-05-30 CN CN202311285883.0A patent/CN117357524A/zh active Pending
- 2018-05-30 CN CN202510610323.0A patent/CN120732857A/zh active Pending
- 2018-05-30 RS RS20240113A patent/RS65230B1/sr unknown
- 2018-05-30 LT LTEP23219933.1T patent/LT4327869T/lt unknown
- 2018-05-30 ES ES18733415T patent/ES2970419T3/es active Active
- 2018-05-30 SI SI201831052T patent/SI3630114T1/sl unknown
- 2018-05-30 HR HRP20241738TT patent/HRP20241738T1/hr unknown
- 2018-05-30 EP EP23219922.4A patent/EP4327868A2/en not_active Withdrawn
- 2018-05-30 ES ES23219933T patent/ES3065413T3/es active Active
- 2018-05-30 DK DK22165669.7T patent/DK4062916T3/da active
- 2018-05-30 DK DK23219933.1T patent/DK4327869T3/da active
- 2018-05-30 EP EP23189734.9A patent/EP4245366A3/en not_active Withdrawn
- 2018-05-30 ES ES23219949T patent/ES3065434T3/es active Active
- 2018-05-30 EP EP22165647.3A patent/EP4062915A1/en not_active Withdrawn
- 2018-05-30 LT LTEPPCT/US2018/035032T patent/LT3630114T/lt unknown
- 2018-05-30 TW TW107118443A patent/TWI795408B/zh active
- 2018-05-30 PL PL18733415.6T patent/PL3630114T3/pl unknown
- 2018-05-30 PT PT232199497T patent/PT4324522T/pt unknown
- 2018-05-30 EP EP23219949.7A patent/EP4324522B1/en active Active
- 2018-05-30 FI FIEP23219933.1T patent/FI4327869T3/fi active
- 2018-05-30 PT PT232199331T patent/PT4327869T/pt unknown
- 2018-05-30 LT LTEP22165669.7T patent/LT4062916T/lt unknown
- 2018-05-30 HR HRP20260335TT patent/HRP20260335T1/hr unknown

Also Published As

Publication number	Publication date
TWI775453B (zh)	2022-08-21
DK3630114T3 (da)	2024-01-29
RS67849B1 (sr)	2026-03-31
SI4062916T1 (sl)	2025-04-30
EP4327869A3 (en)	2024-05-22
TW201900165A (zh)	2019-01-01
HRP20240061T1 (hr)	2024-03-29
EP4324522A2 (en)	2024-02-21
CN119587544A (zh)	2025-03-11
EP4635496A1 (en)	2025-10-22
ES2970419T3 (es)	2024-05-28
EP4062915A1 (en)	2022-09-28
HUE069837T2 (hu)	2025-04-28
CN117357524A (zh)	2024-01-09
FI4324522T3 (fi)	2026-03-09
DK4324522T3 (da)	2026-03-16
SI3630114T1 (sl)	2024-03-29
LT4327869T (lt)	2026-03-25
PT4327869T (pt)	2026-03-12
SMT202400037T1 (it)	2024-03-13
EP4245366A9 (en)	2023-12-06
FI3630114T3 (fi)	2024-01-30
DK4062916T3 (da)	2025-01-13
FI4062916T3 (fi)	2025-01-10
EP4245366A2 (en)	2023-09-20
RS66376B1 (sr)	2025-02-28
EP4327869B1 (en)	2025-12-10
SMT202500016T1 (it)	2025-03-12
ES3052647T3 (en)	2026-01-12
EP4374918B1 (en)	2025-07-16
HUE065615T2 (hu)	2024-06-28
EP4245366A3 (en)	2023-11-29
PL4062916T3 (pl)	2025-03-17
EP4062916A1 (en)	2022-09-28
FI4327869T3 (fi)	2026-03-09
TWI795408B (zh)	2023-03-11
TWI894750B (zh)	2025-08-21
SMT202600114T1 (it)	2026-05-12
SMT202600113T1 (it)	2026-05-12
PT4324522T (pt)	2026-03-13
EP3630114B9 (en)	2026-05-20
HRP20260335T1 (hr)	2026-04-10
HRP20241738T1 (hr)	2025-02-28
EP4324522A3 (en)	2024-05-22
LT4324522T (lt)	2026-03-25
PT3630114T (pt)	2024-02-01
RS65230B1 (sr)	2024-03-29
LT3630114T (lt)	2024-02-12
EP4327869A2 (en)	2024-02-28
EP4374918A3 (en)	2024-08-14
EP4062916B1 (en)	2024-10-09
PL4327869T3 (pl)	2026-04-27
ES3002433T3 (en)	2025-03-06
PT4062916T (pt)	2025-01-13
ES3065434T3 (en)	2026-05-06
TW202440104A (zh)	2024-10-16
EP4374918A2 (en)	2024-05-29
SI4327869T1 (sl)	2026-05-29
EP3630114B1 (en)	2023-11-01
LT4062916T (lt)	2025-01-10
TW202322814A (zh)	2023-06-16
EP3630114A1 (en)	2020-04-08
CN111278438A (zh)	2020-06-12
SI4324522T1 (sl)	2026-05-29
CN120732857A (zh)	2025-10-03
EP4324522B1 (en)	2025-12-10
EP4327868A2 (en)	2024-02-28
PL3630114T3 (pl)	2024-03-25
DK4327869T3 (da)	2026-03-16
HRP20260346T1 (hr)	2026-04-24
TW202140000A (zh)	2021-11-01
RS67861B1 (sr)	2026-04-30
ES3065413T3 (en)	2026-05-06

Publication	Publication Date	Title
ZA202006746B (en)	2023-03-29	Methods of treatment
GB201804514D0 (en)	2018-05-02	Treatment of pyroptosis
GB201706406D0 (en)	2017-06-07	Method of treatment
EP3684342C0 (en)	2024-04-24	TREATMENT PROCEDURES
ZA201705997B (en)	2019-07-31	Method of preventing or treating hearing loss
GB201815588D0 (en)	2018-11-07	Method of treatment
ZA201705847B (en)	2020-03-25	Treatment of pain
GB201804515D0 (en)	2018-05-02	Treatment of necroptosis
ES3065413T3 (en)	2026-05-06	Methods of treating fabry patients having renal impairment
SG11202102878TA (en)	2021-04-29	Treatment methods
SG11202102827YA (en)	2021-04-29	Treatment methods
SG11202005850VA (en)	2020-07-29	Methods of treatment of hypertrigl yceridemia
GB201717555D0 (en)	2017-12-06	Blood filter
GB201801249D0 (en)	2018-03-14	Methods of treatment
GB201720439D0 (en)	2018-01-24	Method of treatment
GB201718589D0 (en)	2017-12-27	Method of treatment
GB201709554D0 (en)	2017-08-02	Method of treatment
GB201706642D0 (en)	2017-06-07	Method of treatment
GB201706452D0 (en)	2017-06-07	Method of treatment
GB201706398D0 (en)	2017-06-07	Method of treatment
GB201706404D0 (en)	2017-06-07	Method of treatment